about
Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer.The heterogeneous landscape of ALK negative ALCL.Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L BromodomainsChemical probes targeting epigenetic proteins: Applications beyond oncology.Exploiting Epigenetic Alterations in Prostate Cancer.Bromodomain protein 4 is a novel predictor of survival for gastric carcinomaNMR-based platform for fragment-based lead discovery used in screening BRD4-targeted compoundsEffect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability.Bromodomain and Extra-terminal (BET) Protein Inhibitors Suppress Chondrocyte Differentiation and Restrain Bone Growth.Suppression of Enhancer Overactivation by a RACK7-Histone Demethylase ComplexBET Inhibition Attenuates Helicobacter pylori-Induced Inflammatory Response by Suppressing Inflammatory Gene Transcription and Enhancer Activation.Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics.Nucleic acid clamp-mediated recognition and stabilization of the physiologically relevant MYC promoter G-quadruplex.Pharmacological targeting of BET proteins inhibits renal fibroblast activation and alleviates renal fibrosisChlamydia trachomatis Prevents Apoptosis Via Activation of PDPK1-MYC and Enhanced Mitochondrial Binding of Hexokinase II.Amplification of the NSD3-BRD4-CHD8 pathway in pelvic high-grade serous carcinomas of tubo-ovarian and endometrial origin.Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent.Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs.Epigenomic regulation of oncogenesis by chromatin remodeling.Synthesis and biological evaluation of N-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)benzenesulfonamide derivatives as new BET bromodomain inhibitors for anti-hematologic malignancies activities.Bromodomains in Protozoan Parasites: Evolution, Function, and Opportunities for Drug Development.Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons.Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the RescueEpigenetic balance of gene expression by Polycomb and COMPASS families.Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.The landscape of new drugs in lymphomaMedulloblastoma: Molecular Classification-Based Personal Therapeutics.Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment HitBRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1).Prolyl isomerase PIN1 regulates the stability, transcriptional activity and oncogenic potential of BRD4.Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues.Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition.Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.Epigenetic Basis of Cellular Senescence and Its Implications in Aging.Activity of bromodomain protein inhibitors/binders against asexual-stage Plasmodium falciparum parasites.The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers.Recent Advances in Prostate Cancer Treatment and Drug Discovery.The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.
P2860
Q28076548-E0E94173-D827-4151-A654-17A66A89416FQ30248629-6CEC6541-9CE4-497E-9BC8-B50468597CE3Q33567012-47FF5687-B307-4906-A0A8-35D65B7581E8Q33725257-39EAAD40-96D6-4FA9-8DD1-99CD471AB85DQ33751386-DCE4F98C-EA47-4FD2-A586-4ED0E64BBB99Q33755160-AF044199-C316-4B46-83B8-25CEFA1D3913Q33761645-15CE5BA2-C0E1-46C4-BF51-2C4249E00838Q36033498-06BAC72C-A97E-45C1-A9DB-C87455F4C47DQ36073783-550667EC-A6C8-44D1-BBA3-2ECC406C16EFQ36185007-F5B28BE6-8E8A-4F57-BA2E-9925D74E39E5Q36783309-C5EC4911-B493-4CEA-AFF3-3D6866A7E86DQ36906022-A2333747-4558-47A0-BFC7-998762B7D597Q37156611-C0E461AC-F178-44A8-BFB2-D76890FABB86Q37507524-98D26447-6BE6-4371-A8F9-1D5634AEB79FQ37688355-7507A811-E6BE-47CB-B1AF-3074BA54C194Q37833654-ADB92588-80E2-4D91-83EE-5C440FC5AACBQ38637914-8754B828-47E8-4B69-BA93-B9C94672699FQ38695896-C38DA91E-A986-4259-A8F9-2780A8CD1239Q38707876-8F430EED-D351-4D06-BB2B-5713DE23948EQ38709544-B44C5E2F-33D4-4444-8F42-805A4330A0E1Q38730539-9B730E66-36F6-4303-A31E-582BE8AD8735Q38771703-455584E1-26E9-4D79-A898-757B7643EA86Q38790957-29C76C3D-5C38-4FBB-A342-4EF27966EFDFQ38850598-E85B4B02-D77D-4477-AAA4-1D9C09A80929Q38852455-3E037F17-D8B3-4822-9A75-4109263C9EC1Q39024306-B70210FB-F364-4045-8FED-2B777F6321A0Q39061630-8DAB2035-4BBF-4E13-860F-AE2D495FF4B8Q39225738-9F3AA2F1-D074-4C06-B4C9-408C31FBB9EDQ39821089-45301CA4-E14C-4761-8CB1-CC59730CF88CQ41612803-BA0E3286-F6BA-46ED-8481-99D7F0EAB4F7Q43400620-CEDC143D-4760-410A-9262-DDC773E12F20Q47583420-3CF8BCC4-5760-482D-90C6-E93AAC41788AQ47750108-99222D80-F677-430A-B81F-8221CCC4A073Q47956425-2D975EB5-7589-4176-8A96-05F4766FCF9DQ49523811-092AE079-C1EB-4D60-ABED-946CD49D1272Q52598516-857C3DD4-1303-41F0-BAE1-C67BC3791469Q52680700-78B72A6E-EBE7-4D7B-A701-7767B913090FQ53693522-6E39796C-262D-4B52-B58E-99114EE6B44EQ54111821-50EE00E5-329D-4C10-9D50-5D45BDB4AFD5Q55098659-6213E58F-02DA-4F3A-B345-0BC3E92F42ED
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Targeting BET bromodomains for cancer treatment
@ast
Targeting BET bromodomains for cancer treatment
@en
Targeting BET bromodomains for cancer treatment
@nl
type
label
Targeting BET bromodomains for cancer treatment
@ast
Targeting BET bromodomains for cancer treatment
@en
Targeting BET bromodomains for cancer treatment
@nl
prefLabel
Targeting BET bromodomains for cancer treatment
@ast
Targeting BET bromodomains for cancer treatment
@en
Targeting BET bromodomains for cancer treatment
@nl
P2093
P2860
P3181
P356
P1433
P1476
Targeting BET bromodomains for cancer treatment
@en
P2093
Bernard Haendler
Kathy A Gelato
Marie Jung
Stephan Siegel
P2860
P304
P3181
P356
10.2217/EPI.14.91
P407
P577
2015-01-01T00:00:00Z